OCULAR THERAPEUTIX, INC.

(OCUL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ocular Therapeutix : HC Wainwright Adjusts Price Target on Ocular Therapeutix to $14 From $18, Keeps Buy Rating

10/25/2021 | 07:38am EDT


© MT Newswires 2021
All news about OCULAR THERAPEUTIX, INC.
05/11Berenberg Bank Cuts Price Target on Ocular Therapeutix to $21 From $23, Maintains Buy R..
MT
05/10Ocular therapeutix reports first quarter 2022 financial results and business update
AQ
05/10HC Wainwright Adjusts Price Target on Ocular Therapeutix to $10 From $14, Reiterates Bu..
MT
05/10Piper Sandler Adjusts Price Target on Ocular Therapeutix to $16 From $20, Reiterates Ov..
MT
05/09OCULAR THERAPEUTIX : Q1 Earnings Snapshot
AQ
05/09TRANSCRIPT : Ocular Therapeutix, Inc., Q1 2022 Earnings Call, May 09, 2022
CI
05/09OCULAR THERAPEUTIX, INC Management's Discussion and Analysis of Financial Condition an..
AQ
05/09Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $13.2M, vs. Street Est of $13..
MT
05/09Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/09Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Upd..
BU
More news
Analyst Recommendations on OCULAR THERAPEUTIX, INC.
More recommendations
Financials (USD)
Sales 2022 60,4 M - -
Net income 2022 -71,2 M - -
Net cash 2022 48,0 M - -
P/E ratio 2022 -3,61x
Yield 2022 -
Capitalization 245 M 245 M -
EV / Sales 2022 3,26x
EV / Sales 2023 2,30x
Nbr of Employees 228
Free-Float 99,4%
Chart OCULAR THERAPEUTIX, INC.
Duration : Period :
Ocular Therapeutix, Inc. Technical Analysis Chart | OCUL | US67576A1007 | MarketScreener
Technical analysis trends OCULAR THERAPEUTIX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,19 $
Average target price 17,71 $
Spread / Average Target 455%
EPS Revisions
Managers and Directors
Antony Mattessich President, Chief Executive Officer & Director
Donald Notman Chief Financial Officer
Charles M. Warden Chairman
Peter Jarrett Chief Scientific Officer
Michael H. Goldstein Chief Medical Officer & Ophthalmology President
Sector and Competitors
1st jan.Capi. (M$)
OCULAR THERAPEUTIX, INC.-54.23%245
NOVO NORDISK A/S-3.80%1 677 391
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098